Combination

Broad Capital Acquisition Corp Confirms Funding to Extend Period to Consummate Initial Business Combination to February 13, 2024

Retrieved on: 
Wednesday, January 17, 2024
Combination, Business analyst, BRAC, Acquisition

Dallas, Texas, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Broad Capital Acquisition Corp. (the “Company”) (NASDAQ: BRAC, BRACR, BRACU), a special purpose acquisition company formed by Broad Capital LLC, today announced that on January 11, 2024 it caused to be deposited $60,000 (the “Extension Payment”) into the Company’s trust account for its public stockholders, representing $0.035 per public share, allowing the Company to extend the period of time it has to consummate its initial business combination to February 13, 2024 (the “Monthly Extension”).

Key Points: 
  • Dallas, Texas, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Broad Capital Acquisition Corp. (the “Company”) (NASDAQ: BRAC, BRACR, BRACU), a special purpose acquisition company formed by Broad Capital LLC, today announced that on January 11, 2024 it caused to be deposited $60,000 (the “Extension Payment”) into the Company’s trust account for its public stockholders, representing $0.035 per public share, allowing the Company to extend the period of time it has to consummate its initial business combination to February 13, 2024 (the “Monthly Extension”).
  • The Monthly Extension is the first of the twelve monthly extensions permitted under the Company’s Amended and Restated Certificate of Incorporation, as amended to date.
  • On January 18, 2023, the Company entered into a definitive Agreement and Plan of Merger and Business Combination Agreement (the “Business Combination Agreement”) with Openmarkets Group Pty Ltd, an Australian proprietary limited company (“OMG”), BMYG OMG Pty Ltd, an Australian proprietary limited company, and Broad Capital LLC, a Delaware limited liability company, solely in its capacity as the Company’s sponsor, pursuant to which the Company will enact its initial business combination.

Renesas Debuts Its Lowest Power Consumption, Dual-core Bluetooth Low Energy SoC with Integrated Flash

Retrieved on: 
Thursday, January 18, 2024
Telecommunications, Networks, Hardware, Consumer Electronics, Technology, Semiconductor, Mobile, Wireless, Other Technology, Cortex, Socs, Instrument panel, RCX, Renesas Electronics, LE, ADC, SOC, Multimedia, Radio, Combination, RAM, Flash, POS, Bluetooth Low Energy, CSL, Analog, QSPI, Video game

Renesas Electronics Corporation (TSE: 6723), a premier supplier of advanced semiconductor solutions, today introduced the DA14592 Bluetooth® Low Energy (LE) System-on-Chip (SoC) representing Renesas’ lowest power consumption and smallest, multi-core (Cortex-M33, Cortex-M0+), Bluetooth LE device.

Key Points: 
  • Renesas Electronics Corporation (TSE: 6723), a premier supplier of advanced semiconductor solutions, today introduced the DA14592 Bluetooth® Low Energy (LE) System-on-Chip (SoC) representing Renesas’ lowest power consumption and smallest, multi-core (Cortex-M33, Cortex-M0+), Bluetooth LE device.
  • View the full release here: https://www.businesswire.com/news/home/20240118157661/en/
    Continuing Renesas’ Bluetooth LE SoC leadership in lowest radio power consumption, the DA14592 utilizes a new low-power mode to offer world-class, 2.3mA radio transmit current at 0dBm and 1.2mA radio receive current.
  • Renesas has integrated all external components required to implement a Bluetooth LE solution into the DA14592MOD module.
  • For information about Renesas’ comprehensive development kits and support, including its widely adopted, low-cost, no-licensing fees product line tester, contact Renesas or visit: renesas.com/DA14592 .

Altitude Acquisition Corp. Announces Extension of Deadline to Complete Initial Business Combination

Retrieved on: 
Thursday, January 11, 2024
ALTU, Combination, Altitude

ATLANTA, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Altitude Acquisition Corp. (Nasdaq: ALTUU, ALTU, ALTUW) (“Altitude”), announced today that its board of directors (the “Board”) has extended the date by which Altitude must consummate an initial business combination (the “Deadline Date”) for an additional month, from January 11, 2024 to February 11, 2024.

Key Points: 
  • ATLANTA, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Altitude Acquisition Corp. (Nasdaq: ALTUU, ALTU, ALTUW) (“Altitude”), announced today that its board of directors (the “Board”) has extended the date by which Altitude must consummate an initial business combination (the “Deadline Date”) for an additional month, from January 11, 2024 to February 11, 2024.
  • Altitude’s Amended and Restated Certificate of Incorporation, as amended (the “Charter”), gives the Board the right to extend the Deadline Date, without further stockholder vote, up to three times for an additional one month each time (each, an “Extension”), from December 11, 2023 to up to March 11, 2024.
  • As previously announced, on April 23, 2023, Altitude entered into a business combination agreement (the “Business Combination Agreement”) with Picard Medical, Inc. (“Picard”) and the other parties thereto, which provides for a business combination between Altitude and Picard.
  • The purpose of this monthly Extension is to provide Altitude with additional time to consummate the proposed business combination with Picard.

Noventiq and Corner Growth Acquisition Corp. File Form F-4 Ahead of Proposed Nasdaq Listing

Retrieved on: 
Tuesday, January 2, 2024
Security, Technology, Other Technology, Software, Internet, Hardware, London Stock Exchange, Microsoft, Cayman Islands, Corner, Multimedia, AWS, Business analyst, Business, Sale, GM, Form, Acquisition, Moscow Exchange, Register, Security association, Bank statement, AI, Communication, Name, Cayman, Adjustment, Proxy, Combination, Prospectus, SCA, F-4, Amazon Web Services

Noventiq recently entered into a multi-year Strategic Collaboration Agreement (SCA) with Amazon Web Services (AWS).

Key Points: 
  • Noventiq recently entered into a multi-year Strategic Collaboration Agreement (SCA) with Amazon Web Services (AWS).
  • As part of its investment in AI technologies, Noventiq recently launched Weaver Peer, a knowledge-based AI assistant, designed and built in-house by Noventiq subsidiary, Intellya.
  • On May 4, 2023, Noventiq and Corner Growth entered into a business combination agreement that is expected to result in the combined company (“Combined Company”) being listed on Nasdaq under the symbol “NVIQ”.
  • This communication relates to the proposed Business Combination between Noventiq and Corner Growth.

Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)

Retrieved on: 
Tuesday, January 2, 2024
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Diarrhea, DSM-IV codes, Cannabidiol, Lethargy, Partnership, Constipation, Clobazam, Aes, Lamotrigine, Caregiver, Principal, Research, LGS, TID, DEE, ASMS, Medication, Data, Physician, Somnolence, MD, Doctor of Philosophy, DS, SAE, Seizure, Combination, Pharmacokinetics, Appetite, Participation, Patient, Diagnosis, Safety, Levetiracetam, MSCE, Pharmaceutical industry

Of the 52 participants enrolled in the study, 43 participants were randomized to bexicaserin (DS=4, LGS=24, DEE Other=15) and 9 to placebo (DS=0, LGS=5, DEE Other=4).

Key Points: 
  • Of the 52 participants enrolled in the study, 43 participants were randomized to bexicaserin (DS=4, LGS=24, DEE Other=15) and 9 to placebo (DS=0, LGS=5, DEE Other=4).
  • The median number of countable motor seizures per 28-day period at baseline was 38.8 in the bexicaserin group compared to 20.8 in the placebo group.
  • Most participants (85.7%) in the bexicaserin treated group (n=35) that started the maintenance period tolerated the highest dose (12 mg).
  • 100% of the participants who completed the PACIFIC Study elected to enroll in the ongoing 52-week open-label extension study.

PSI Group, a Long-Established Global Logistics Service Provider, Plans to List on Nasdaq Through Merger with AIB Acquisition Corporation

Retrieved on: 
Thursday, December 28, 2023
Yee, Atmosphere, Partnership, Partner, Business analyst, LLP, Acquisition, Hope, AIB, Combination, Security (finance), Cooley LLP, PSI, Financial adviser

PSI is one of the renowned air freight forwarding specialists in Hong Kong, providing global logistics and supply chain service to clients of various industries, including postal operators, e-Commerce merchants, senders and consignees.

Key Points: 
  • PSI is one of the renowned air freight forwarding specialists in Hong Kong, providing global logistics and supply chain service to clients of various industries, including postal operators, e-Commerce merchants, senders and consignees.
  • Founded in 1993, the company is headquartered in Hong Kong with a global network, operating through its subsidiaries, namely Profit Sail Int’l Express (H.K.)
  • The company is managed and run by a group of professionals with over 30 years of combined expertise in the logistics and air/ocean freight industries.
  • Cooley LLP is serving as U.S. legal advisor, and Ogier is serving as Cayman Islands legal advisor to PSI in connection with the Business Combination.

SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma

Retrieved on: 
Wednesday, December 27, 2023
Patient, DCR, Immunotherapy, National Cancer Institute, Rated R, Neoplasm, Survival, RECIST, GPS, CD8, Male, Standard of care, Progression-free survival, Trial of the century, Nivolumab, WT1, MPM, SLS, Combination, OS, PFS, Female, Pharmaceutical industry

NEW YORK, Dec. 27, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel therapies for a broad range of cancer indications, today announced follow-up clinical/immune-response data from a Phase 1 investigator-sponsored clinical trial of its lead clinical candidate, galinpepimut-S (GPS), combined with the checkpoint inhibitor nivolumab (Opdivo®) in patients with refractory/relapsed malignant pleural mesothelioma (MPM).

Key Points: 
  • Nine out of ten patients (90%) had sufficient samples collected to be analyzed for GPS-specific immune response.
  • All enrolled patients had either received and progressed with or were refractory to frontline pemetrexed-based chemotherapy.
  • Additional analyses for the correlation of immune response and survival benefit were performed.
  • Among the nine evaluable patients, four patients had a CD4+ immune response (44.4%) and three patients had a CD8+ immune response (33.3%) to GPS.

SomaLogic Issues Letter to Stockholders Reiterating Recommendation for Value Maximizing Merger with Standard BioTools

Retrieved on: 
Thursday, December 21, 2023
SomaLogic, Proteomics, Motivation, Risk, Sale, Standard BioTools, Research, Mergers and acquisitions, NDA, Special, Combination, Shareholder, ALL, Standard, Holding company

BOULDER, Colo., Dec. 21, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc. (Nasdaq: SLGC) today issued an open letter to stockholders highlighting the value maximizing merger entered into with Standard BioTools (Nasdaq: LAB) on October 4, 2023. The Company also filed an investor presentation, which can be found on the investor page of SomaLogic’s website at https://investors.somalogic.com/static-files/daa110f7-0cc3-4eaf-ba78-e0c....

Key Points: 
  • On January 4, 2024, we are holding our Special Stockholder Meeting to vote on our proposed merger with Standard BioTools – a merger that we believe is in the best interests of all SomaLogic stockholders.
  • Thank you for your support,
    The Company urges all stockholders to vote “FOR” the value maximizing transaction on the SomaLogic proxy card today.
  • A special meeting of SomaLogic stockholders is scheduled to be held virtually in connection with the proposed merger on January 4, 2024, at 12 p.m.
  • The merger remains on track to close in the first quarter of 2024, subject to approval by SomaLogic and Standard BioTools stockholders and satisfaction of other customary closing conditions.

Jupiter Acquisition Corporation Announces Mutually Agreed Termination of Business Combination Agreement With Filament Health Corp., Cancellation of Special Meeting of Stockholders and Redemption of Public Shares

Retrieved on: 
Wednesday, December 20, 2023
Transfer, Charter, Tax, Business analyst, Class, Sound, Combination, IPO, Security (finance)

Hobe Sound, FL, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Jupiter Acquisition Corporation (NASDAQ:JAQC) (“Jupiter”) today announced the mutually agreed termination of the previously announced business combination agreement with Filament Health Corp. (the “Business Combination Agreement”).

Key Points: 
  • Hobe Sound, FL, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Jupiter Acquisition Corporation (NASDAQ:JAQC) (“Jupiter”) today announced the mutually agreed termination of the previously announced business combination agreement with Filament Health Corp. (the “Business Combination Agreement”).
  • The special meeting of stockholders of Jupiter scheduled to reconvene on Thursday, December 28, 2023, at 12:00 p.m. Eastern Time, at which stockholders of Jupiter were to be asked to vote to approve the Business Combination Agreement and the business combination contemplated thereby, among other related matters, has been cancelled.
  • The per-share redemption price for the public shares is expected to be approximately $10.34 (as finally determined, the “Redemption Amount”).
  • Beneficial owners of public shares held in “street name,” however, will not need to take any action in order to receive the Redemption Amount.

Broad Capital Acquisition Corp Confirms Funding to Extend Period to Consummate Initial Business Combination to January 13, 2024

Retrieved on: 
Monday, December 18, 2023
BRAC, Business analyst, Acquisition, Combination

Dallas, Texas, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Broad Capital Acquisition Corp. (the “Company”) (NASDAQ: BRAC, BRACR, BRACU), a special purpose acquisition company formed by Broad Capital LLC, today announced that on December 12, 2023 it caused to be deposited $150,000 (the “Extension Payment”) into the Company’s trust account for its public stockholders, representing $0.0332 per public share, allowing the Company to extend the period of time it has to consummate its initial business combination to January 13, 2024 (the “Monthly Extension”).

Key Points: 
  • Dallas, Texas, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Broad Capital Acquisition Corp. (the “Company”) (NASDAQ: BRAC, BRACR, BRACU), a special purpose acquisition company formed by Broad Capital LLC, today announced that on December 12, 2023 it caused to be deposited $150,000 (the “Extension Payment”) into the Company’s trust account for its public stockholders, representing $0.0332 per public share, allowing the Company to extend the period of time it has to consummate its initial business combination to January 13, 2024 (the “Monthly Extension”).
  • The Monthly Extension is the twelfth of the twelve monthly extensions permitted under the Company’s governing documents.
  • On January 18, 2023, the Company entered into a definitive Agreement and Plan of Merger and Business Combination Agreement (the “Business Combination Agreement”) with Openmarkets Group Pty Ltd, an Australian proprietary limited company (“OMG”), BMYG OMG Pty Ltd, an Australian proprietary limited company, and Broad Capital LLC, a Delaware limited liability company, solely in its capacity as the Company’s sponsor, pursuant to which the Company will enact its initial business combination.